Thomson Reuters
Report: VCs put more into fewer medtech deals last year
Venture capitalists put more cash into fewer deals backing medical device companies last year, according to the MoneyTree report, meaning that the average deal value rose nearly 28% in 2014.
Shares soar for InVivo after spinal cord study update | Medtech Wall Street news for the week of November 17, 2014
Venture capital investment in medtech grows in Q3
Venture capitalists put more cash into more deals for medical device companies during the 3rd quarter, according to a report from PricewaterhouseCoopers.
Medical device companies pulled down $586 million in 78 deals during the 3rd quarter, up 13% in dollars and 18% in deal volume compared with Q3 2013.
Five major factors will determine the future of the medical device industry | Medtech Wall Street news for the week of October 20, 2014
Medtech VC deals post double-digit increases in Q3
Venture capital shops got behind medtech during the 3rd quarter, increasing their spend and the number of deals compared with the same period last year, according to the MoneyTree report from PricewaterhouseCoopers and the National Venture Capital Assn., based on Thomson Reuters data.
ForSight Vision5 pulls down a $15 million Series C round | Medtech funding stories for the week of Apr. 21, 2014
Report: Medtech VC deals down, values up in Q1
Venture capitalists put more skin in fewer deals during the 1st quarter, amid an overall decline in life science deals, according to a survey of VC shops.
The number of deals for the medical device & equipment sector dropped 37% to 61 transactions, but the total value of those deals rose 28% to $588 million, according to the MoneyTree report from PricewaterhouseCoopers LLP and the National Venture Capital Assn., based on data provided by Thomson Reuters.
VC spend in life sciences grew in 2011 | Wall Street Beat
Venture capital funding of life science startups, including biotech and medical device enterprises, rose by 21% last year, according to PricewaterhouseCoopers.
VCs dropped $7.5 billion on 785 life sciences deals during the year, according to a PwC report, "Zigzagging Upward," compiled using data from the PricewaterhouseCoopers LLP/National Venture Capital Assn. MoneyTree Report and Thomson Reuters.
